StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on RVNC. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Piper Sandler lowered Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 12th. HC Wainwright downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 13th. Stifel Nicolaus cut their price target on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, Needham & Company LLC lowered shares of Revance Therapeutics from a “moderate buy” rating to a “hold” rating in a report on Tuesday, August 13th. Ten research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Revance Therapeutics has an average rating of “Hold” and an average price target of $10.50.

Revance Therapeutics Trading Down 2.1 %

RVNC opened at $5.22 on Wednesday. The company has a market cap of $545.22 million, a P/E ratio of -1.44 and a beta of 0.98. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $10.71. The business’s 50-day moving average price is $5.67 and its 200-day moving average price is $4.25.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. The company had revenue of $65.39 million for the quarter, compared to analysts’ expectations of $66.30 million. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period last year, the company posted ($0.80) EPS. Equities research analysts forecast that Revance Therapeutics will post -1.53 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Nebula Research & Development LLC bought a new stake in shares of Revance Therapeutics during the fourth quarter valued at approximately $926,000. Sierra Summit Advisors LLC bought a new stake in shares of Revance Therapeutics in the 4th quarter worth $760,000. HighPoint Advisor Group LLC purchased a new position in shares of Revance Therapeutics in the fourth quarter worth $98,000. Los Angeles Capital Management LLC bought a new position in shares of Revance Therapeutics during the first quarter valued at $457,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Revance Therapeutics by 67.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 6,826 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.